Centene (CNC), Pyx Health Unite to Treat Mental Health Issues

Centene Corporation's
CNC Managed
Care brand and a wholly-owned subsidiary, Delaware First Health,
announced its partnership with Pyx Health. Under this partnership,
Delaware First Health's members will get access to Pyx Health's
compassionate human support program and interactive technology
platform. These initiatives will be able to help detect loneliness
and provide users with relevant sources to aid in the mental and
social health recovery process.

This move bodes well for Centene as
Medicaid members will be able to use the resources at any time of
the day, thereby increasing patient satisfaction. Loneliness is
often found linked to chronic diseases and illnesses and through
this unique technology, the company can reduce its claim costs as
healthy insured people are more likely to reduce the impact of
chronic diseases. Delaware First Health plans to roll out the
mobile app to its members in 2024, thereby reducing higher rates of
obesity, anxiety, heart diseases as a result of loneliness.

With the onset of the pandemic,
loneliness became a widespread problem leading to further serious
diseases. Innovative technology coupled with human intervention is
expected to improve patient satisfaction and thereby improve CNC's
Medicaid quality scores. This will further translate into better
retention rates for Centene.

The Pyx Health Solution's app uses
empathetic and data-driven technology to recognize loneliness among
people. Consistent human intervention is correlated with improved
health outcomes. This move highlights Centene's efforts to improve
overall health results as well as reduce mental health
emergencies.

Moreover, to get access to Pyx
Health's revolutionary technology, more people may be lured to
enroll in one of CNC's Medicaid plans. This, in turn, will drive
its membership growth and boost premiums.

Shares of Centene have rallied 5.9%
in the past three months against the
industry's
5.4% decline. CNC currently carries a Zacks Rank #3 (Hold).

Image
Source: Zacks Investment Research

Stocks to Consider

Some better-ranked stocks in
the
Medical space
are
The Cigna Group
CI,
ANI Pharmaceuticals, Inc.
ANIP and
Cencora, Inc.
COR. Each of
these companies currently carries a Zacks Rank #2 (Buy). You can
see

the complete list of today's Zacks #1 Rank (Strong Buy)
stocks here
.

Cigna's earnings surpassed the
Zacks Consensus Estimate in each of the last four quarters, the
average surprise being 2.9%. The Zacks Consensus Estimate for CI's
2024 earnings suggests 13% growth from the year-ago reported
figure.

The consensus estimate for CI's
2024 earnings has moved 0.3% north in the past 30 days. Shares of
Cigna have gained 16.9% in the past year.

ANI Pharmaceuticals' earnings
outpaced the Zacks Consensus Estimate in each of the trailing four
quarters, the average surprise being 105.8%. The Zacks Consensus
Estimate for ANIP's 2023 earnings is pegged at $4.51 per share,
which indicates more than a two-fold increase from the prior-year
reported figure. The same for revenues indicates growth of 51.1%
from the year-ago reported figure.

The consensus estimate for ANIP's
2023 earnings has moved 0.7% north in the past 30 days. Shares of
ANIP Pharmaceuticals have gained 52.4% in a year.

Cencora's earnings beat the Zacks
Consensus Estimate in each of the trailing four quarters, the
average surprise being 6.7%. The Zacks Consensus Estimate for COR's
fiscal 2024 earnings and revenues indicates a rise of 12% and
11.5%, respectively, from the year-ago reported levels.

The Zacks Consensus Estimate for
COR's fiscal 2024 earnings has moved 4.3% north in the past 30
days. Shares of Cencora have rallied 52.1% in the past year.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their
favorite to skyrocket +100% or more in months to come. From those
5, Director of Research Sheraz Mian hand-picks one to have the most
explosive upside of all.

It's a little-known chemical company that's up 65% over last
year, yet still dirt cheap. With unrelenting demand, soaring 2022
earnings estimates, and $1.5 billion for repurchasing shares,
retail investors could jump in at any time.

This company could rival or surpass other recent Zacks' Stocks
Set to Double like Boston Beer Company which shot up +143.0% in
little more than 9 months and NVIDIA which boomed +175.9% in one
year.

Free:
See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report

Cigna Group (CI): Free Stock Analysis Report

Cencora, Inc. (COR): Free Stock Analysis Report

Centene Corporation (CNC): Free Stock Analysis Report

ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research